Students will participate in ongoing research evaluating a patented technology for developing treatments for Breast Cancer patients.
For-Robin, Inc., founded in 2012 is an antibody immunotherapy company whose primary mission is developing treatments for Breast Cancer (BrCa) patients. Our patented technology, monoclonal antibody, JAA-F11 and humanized variants, hJAA-F11, targets all BrCa cell subtypes including triple negative BrCa where no targeted therapy currently exists. For-Robin is developing hJAA-F11 for adjunct therapy of BrCa and lung cancer either directly or as antibody-drug conjugates. JAA-F11 should be also be applicable for treatment of colon, prostate, ovarian and bladder cancer patients. Our technology will have significant potential for broad future applications.
Students will acquire skills related to animal handling, tumor imaging, use of the microPET and the For-Robin goals of moving hJAA-F11 towards clinical trials will be furthered. Students will contribute to ongoing research projects.
|Length of commitment||One academic year|
|Level of collaboration||Variable|
|Who is eligible||Must have animal use certification and radiation certification|
Students participating in this project might be interested in and eligible for the Goldwater Scholarship and the National Science Foundation Graduate Research Fellowship. Connect with the Office of Fellowships and Scholarships to learn more.
The specific preparation activities for this project will be customized through discussions between you and your project mentor. Please be sure to ask them for the instructions to complete the required preparation activities.